ClinicalTrials.gg
CompletedNCT02582814Updated Apr 12, 2019Results posted

The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With T1DM

A Phase 3 interventional study of Dapagliflozin 5 mg and Dapagliflozin 10mg in Type 1 Diabetes Mellitus, sponsored by AstraZeneca. Completed at 24 sites in Japan. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-04-12.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
151
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 — 2 open to participants now, 5 under way, 2 of them phase 3. dapagliflozin · Diabetes Mellitus, Type 1.

Enrollment
4th of 23
151 · median 43
Started
2015
with 3 others
Phase 3
7 of 23
none open now
Registered
6th of 23
by date
Lead sponsor
5 of 23
AstraZeneca

Among the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, this one is the 4th largest by enrollment, is one of 4 that started in 2015, is one of 7 in phase 3, and was the 6th registered.

Diabetes Mellitus, Type 1

3,756 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing dapagliflozin in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This study will enroll eligible subjects into a long-term safety study (Part B).

Japanese male and female patients with T1DM and age 18 to 75 years, with inadequate glycemic control on insulin defined as HbA1c ≥ 7.5% and ≤ 10.5% at screening visit. As a condition of enrollment, subjects must be on a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the screening visit. The study design of Part B is a randomized, open-label, 2 arm, parallel-group design. 140 Japanese subjects in total will be randomized in a 1:1 ratio into one of the two treatment arms; dapagliflozin 5 mg or dapagliflozin 10 mg.

03

Conditions studied

  • Type 1 Diabetes Mellitus

Keywords

  • Japanese patients with type 1 diabetes with inadequate glycemic control on insulin
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Written
  • Diagnosis of T1DM. In addition, the following criteria also needs to be met; Central laboratory test of C-peptide \< 0.7 ng/mL
  • Insulin use for at least 12 months prior to the enrolment per subject report or medical records and Method of insulin administration (MDI or CSII) must have been unchanged for at least 3 months prior to the enrolment per subject report or medical records. Subjects must be taking a total daily insulin dose of ≥ 0.3 U/kg/day for at least 3 months prior to the enrolment. If on MDI insulin administration subject must be on ≥ 3x injections per day.
  • Japanese men and women
  • Screening Visit: Central laboratory ≥ 7.5% and ≤ 10.5%
  • ≥ 20.0 kg/m² at visit 1
  • Age 18 to 75 years, inclusive

Exclusion criteria

Exclusion Criteria:

  • Target Disease Exceptions History of T2DM Maturity onset diabetes of young (MODY) Any anti-hyperglycemic agent use, other than α-GI or insulin, within 1 month prior to the enrolment.

Use of thiazolidinediones within 6 months prior to the enrolment History of DKA requiring medical intervention within 1 month prior to the enrolment History of hospital admission for glycemic control (either hyperglycemia or hypoglycemia) within 1 month prior to the enrolment

  • Medical History and Concurrent Diseases within 5 years of the enrolment (with the exception of treated basal cell or treated squamous cell carcinoma) History of bladder cancer History of radiation therapy to the lower abdomen or pelvis at any time
  • Physical and Laboratory Test Findings (AST) > 3x (ULN) Alanine aminotransferase (ALT) > 3x ULN Serum total (TB) > 2.0 mg/dL (34.2 μmol/L) Estimated (eGFR) by the Japanese Society of Nephrology formula ≤ 45 mL/min/1.73m2 ≤ 11.0 g/dL (110 g/L) for men; hemoglobin ≤ 10.0 g/dL (100 g/L) for women.

Positive for surface antigen or anti- virus antibody Abnormal Free T4

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
151 participants (actual)

Study arms

  • Experimental
    dapagliflozin 5mg + insulin

    dapagliflozin tablet 5mg + adjustable insulin

    Drug: Dapagliflozin 5 mg

  • Experimental
    dapagliflozin 10mg + insulin

    dapagliflozin tablet 10mg + adjustable insulin

    Drug: Dapagliflozin 10mg

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Adverse Event Summary

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  2. Hypoglycemia

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  3. Diabetic Ketoacidosis (DKA)

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  4. Vital Signs (Heart Rate)

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  5. ECGs

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  6. Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

  7. Vital Signs (Blood Pressure)

    To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

    Time frame: From baseline to 52 weeks

Secondary outcomes

  1. Adjusted Change From Baseline in HbA1c

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  2. Adjusted Percent Change From Baseline in Total Daily Insulin Dose

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  3. Adjusted Percent Change From Baseline in Body Weight

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  4. Adjusted Change From Baseline in Glycoalbumin

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  5. Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  6. Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

    Time frame: From baseline to 24/52 weeks

  7. Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

    Time frame: From baseline to 24/52 weeks

  8. Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

    Time frame: From baseline to 24/52 weeks

  9. Proportion of Subjects Achieving HbA1c < 7.0 Percent

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

    Time frame: From baseline to 24/52 weeks

  10. Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg

    To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

    Time frame: From baseline to 24/52 weeks

07

Results

Posted Apr 12, 2019

Participant flow

Participant flow — Overall Study
MilestoneDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Started7675
Completed6768
Not completed97
Withdrew: Study-specific withdrawal criteria10
Withdrew: Withdrawal by subject43
Withdrew: Adverse event44

Outcome measures

PrimaryOverall Adverse Event Summary

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Count of participants · Participants
Overall Adverse Event Summary
ParticipantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Adverse Events — At least one events6755
Related Adverse Events — At least one events2322
SAE — At least one events73
AEs leading to discontinuation — At least one events44
Death — At least one events00
PrimaryHypoglycemia

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Count of participants · Participants
Hypoglycemia
ParticipantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Any Hypoglycemia Episodes — At least one events7575
Severe Hypoglycemia — At least one events25
Documented Symptomatic Hypoglycemia — At least one events6773
Asymptomatic Hypoglycemia — At least one events6064
Probable Symptomatic Hypoglycemia — At least one events1314
Relative Hypoglycemia — At least one events1411
PrimaryDiabetic Ketoacidosis (DKA)

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Count of participants · Participants
Diabetic Ketoacidosis (DKA)
ParticipantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Definite DKA — At least one events21
Possible DKA — At least one events10
Unlikely DKA — At least one events00
SecondaryAdjusted Change From Baseline in HbA1c

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · percent
Adjusted Change From Baseline in HbA1c
percentDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-0.52 (-0.66 to -0.38)-0.66 (-0.80 to -0.53)
Week 52-0.33 (-0.50 to -0.15)-0.36 (-0.53 to -0.18)
SecondaryAdjusted Percent Change From Baseline in Total Daily Insulin Dose

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · percent change
Adjusted Percent Change From Baseline in Total Daily Insulin Dose
percent changeDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-15.30 (-18.55 to -11.92)-15.14 (-18.43 to -11.73)
Week 52-12.27 (-15.92 to -8.46)-13.13 (-16.77 to -9.33)
SecondaryAdjusted Percent Change From Baseline in Body Weight

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · percent change
Adjusted Percent Change From Baseline in Body Weight
percent changeDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-3.88 (-4.74 to -3.02)-5.26 (-6.11 to -4.41)
Week 52-4.25 (-5.29 to -3.21)-5.96 (-6.98 to -4.93)
SecondaryAdjusted Change From Baseline in Glycoalbumin

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · percent
Adjusted Change From Baseline in Glycoalbumin
percentDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-2.26 (-2.83 to -1.70)-2.63 (-3.22 to -2.04)
Week 52-1.49 (-2.18 to -0.77)-1.68 (-2.41 to -0.96)
SecondaryAdjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · mg/dL
Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG
mg/dLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-9.37 (-15.80 to -2.94)-15.06 (-21.62 to -8.51)
Week 52-11.62 (-18.62 to -4.62)-12.93 (-19.99 to -5.88)
SecondaryAdjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy.

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · mg/dL
Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG
mg/dLDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-2.33 (-11.18 to 6.51)-10.08 (-19.04 to -1.12)
Week 52-6.40 (-15.45 to 2.64)-5.24 (-14.32 to 3.83)
SecondaryProportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

Time frame:
From baseline to 24/52 weeks
Reported as:
Number · percentage of participants
Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia
percentage of participantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 2460.8 (48.8 to 72.0)61.3 (49.4 to 72.4)
Week 5251.4 (39.4 to 63.1)41.3 (30.1 to 53.3)
SecondaryProportion of Subjects Achieving HbA1c Reduction of 0.5 Percent

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

Time frame:
From baseline to 24/52 weeks
Reported as:
Number · percentage of participants
Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent
percentage of participantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 2462.2 (50.1 to 73.2)66.7 (54.8 to 77.1)
Week 5251.4 (39.4 to 63.1)45.3 (33.8 to 57.3)
SecondaryProportion of Subjects Achieving HbA1c < 7.0 Percent

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

Time frame:
From baseline to 24/52 weeks
Reported as:
Number · percentage of participants
Proportion of Subjects Achieving HbA1c < 7.0 Percent
percentage of participantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 249.5 (3.9 to 18.5)5.3 (1.5 to 13.1)
Week 526.8 (2.2 to 15.1)2.7 (0.3 to 9.3)
SecondaryAdjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg

To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin

Time frame:
From baseline to 24/52 weeks
Reported as:
Least squares mean · mmHg
Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg
mmHgDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Week 24-5.8 (-11.2 to -0.3)-12.0 (-19.0 to -5.0)
Week 52-9.8 (-15.1 to -4.5)-14.2 (-20.7 to -7.6)
PrimaryVital Signs (Heart Rate)

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Mean · bpm
Vital Signs (Heart Rate)
bpmDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Vital Signs (Heart Rate)-0.3 ± 10.070.4 ± 8.89
PrimaryECGs

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Count of participants · Participants
ECGs
ParticipantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Baseline — NORMAL6567
Baseline — ABNORMAL118
Baseline — NOT REPORTED00
Week 52 — NORMAL6967
Week 52 — ABNORMAL58
Week 52 — NOT REPORTED20
PrimaryClinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Count of participants · Participants
Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality)
ParticipantsDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Hematocrit (> 55%)10
Hemoglobin (> 18g/dL)21
Creatinine (>1.5 x ULN pre Rx)01
Creatin kinase (> 5x ULN)11
Bicarbonate (<= 13 mEq/L)10
P (<=1.8/2.1mg/dL for age<=/>65)11
UACR (> 1800mg/g)01
PrimaryVital Signs (Blood Pressure)

To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy.

Time frame:
From baseline to 52 weeks
Reported as:
Mean · mmHg
Vital Signs (Blood Pressure)
mmHgDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
Change from baseline in SBP(mmHg) at Week 52-3.4 ± 11.41-2.9 ± 12.55
Change from baseline in DBP(mmHg) at Week 52-0.6 ± 8.21-1.0 ± 7.89

Adverse events

Collected over 1 year. Non-serious adverse event (AE): onset on or after the 1st day of dose up to on or prior to the last day of dose plus 4 days. Serious AE: onset on or after the 1st day of dose up to on or prior to the last day of dose plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dapagliflozin 5mg + Insulin0/76 (0%)7/76 (9.2%)66/76 (86.8%)
Dapagliflozin 10mg + Insulin0/75 (0%)3/75 (4%)55/75 (73.3%)
Most frequent serious events
Most frequent serious events
EventDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
DIABETIC KETOACIDOSISMetabolism and nutrition disorders2/761/75
VITREOUS HAEMORRHAGEEye disorders0/761/75
COLITISGastrointestinal disorders0/761/75
HYPOGLYCAEMIC COMANervous system disorders0/761/75
ATRIAL FIBRILLATIONCardiac disorders1/760/75
HEPATIC FUNCTION ABNORMALHepatobiliary disorders1/760/75
GASTROENTERITISInfections and infestations1/760/75
OSTEOARTHRITISMusculoskeletal and connective tissue disorders1/760/75
ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions1/760/75
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDapagliflozin 5mg + InsulinDapagliflozin 10mg + Insulin
NASOPHARYNGITISInfections and infestations25/7632/75
PHARYNGITISInfections and infestations5/769/75
GASTROENTERITISInfections and infestations7/768/75
KETOSISMetabolism and nutrition disorders4/767/75
POLLAKIURIARenal and urinary disorders7/766/75
HEADACHENervous system disorders4/766/75
BACK PAINMusculoskeletal and connective tissue disorders6/761/75
DENTAL CARIESGastrointestinal disorders0/765/75
ECZEMASkin and subcutaneous tissue disorders4/764/75
THIRSTGeneral disorders4/764/75

Baseline characteristics

Randomized set

Age, Continuous
Age, Continuous(years)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Mean47.7 ± 12.8548.9 ± 12.9348.3 ± 12.86
Sex: Female, Male
Sex: Female, Male(Participants)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Female334275
Male433376
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Asian7675151
Body Mass Index
Body Mass Index(kg/m2)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Mean25.28 ± 3.63524.66 ± 2.80624.97 ± 3.254
Duration of T1DM
Duration of T1DM(years)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Mean14.60 ± 8.42015.94 ± 10.32815.27 ± 9.409
HbA1c
HbA1c(Percent)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
Mean8.43 ± 0.7118.40 ± 0.7158.42 ± 0.711
C-peptide
C-peptide(Participants)Dapagliflozin 5mg + InsulinDapagliflozin 10mg + InsulinTotal
< 0.1 ng/mL6365128
>= 0.1 ng/mL131023
08

Study locations

24 sites
  • Research Site
    Aizu Wakamatsu-shi, Japan
  • Research Site
    Chuo-ku, Japan
  • Research Site
    Fukuoka-shi, Japan
  • Research Site
    Fukuyama-shi, Japan
  • Research Site
    Funabashi-shi, Japan
  • Research Site
    Hamamatsu-shi, Japan
  • Research Site
    Hirosaki-shi, Japan
  • Research Site
    Ise-shi, Japan
  • Research Site
    Kagoshima-shi, Japan
  • Research Site
    Koriyama-shi, Japan
  • Research Site
    Kumamoto-shi, Japan
  • Research Site
    Kunitachi-shi, Japan
  • Research Site
    Minato-ku, Japan
  • Research Site
    Nagoya-shi, Japan
  • Research Site
    Oita-shi, Japan
  • Research Site
    Otsu-shi, Japan
  • Research Site
    Oyama-shi, Japan
  • Research Site
    Sapporo-shi, Japan
  • Research Site
    Sendai-shi, Japan
  • Research Site
    Shinjyuku-ku, Japan
  • Research Site
    Suita-shi, Japan
  • Research Site
    Tama-shi, Japan
  • Research Site
    Tsukuba-shi, Japan
  • Research Site
    Yokohama-shi, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jun 2017, 19 months.

Results were first posted in Apr 2019, 1 year 9 months after primary completion.

Of 79 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 19 months is above that.

Counting every sponsor, half of 108 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2015
First posted
Oct 21, 2015
StartActual
Oct 26, 2015
Primary completionActual
Jun 15, 2017
CompletionActual
Jun 15, 2017
Results first posted
Apr 12, 2019
Last update
Apr 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02582814
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 21, 2015
Start date
Oct 26, 2015
Primary completion
Jun 15, 2017
Completion
Jun 15, 2017
Results posted
Apr 12, 2019
Last update
Apr 12, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion